Natural Product (NP) Details

General Information of the NP (ID: NP4931)
Name
Lycopene
Synonyms
Psi,psi-carotene; all-trans-Lycopene; y,y-Carotene; trans-Lycopene; Lycopene, all-trans-; (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; Lycopene 7; UNII-SB0N2N0WV6; NSC 407322; C.I. 75125; SB0N2N0WV6; CHEBI:15948; MFCD00017350; lycored; NCGC00166291-01; .psi.,.psi.-Carotene; Lycopene (VAN); Redivivo; 15-cis-Lycopene; LYC-O-MATO; Mexoryl SAQ; Tomat-O-Red; LYC; CCRIS 7925; TOMATO LYCOPENE; E160d; EINECS 207-949-1; lycopenes; CI 75125; LyocpenePowder; lycopene group; NSC407322; NSC-407322; Lycopene all-trans-; Lycopene, dispersion; DSSTox_CID_26593; DSSTox_RID_81750; DSSTox_GSID_46593; BSPBio_003389; Lycopene, analytical standard; INS-160D(III); INS NO.160D(III); CHEMBL501174; DTXSID2046593; FEMA NO. 4110; E-160D(III); Lycopene, >=90%, from tomato; AOB5502; (all-E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene; ACT03296; HY-N0287; ZINC8214943; Tox21_112395; LMPR01070257; s3943; AKOS015961276; CS-6378; DB11231; EBD2157929; NCGC00166291-02; NCGC00166291-03; AC-13571; CAS-502-65-8; LS-15428; Lycopene, >=98% (HPLC), from tomato; AB0012241; N2800; 3048-EP2298768A1; 3048-EP2305825A1; C05432; 502L658; Q208130; Q-100561; UNII-32A47J0H1R component OAIJSZIZWZSQBC-GYZMGTAESA-N; UNII-N53I4V2IA6 component OAIJSZIZWZSQBC-GYZMGTAESA-N; Lycopene, United States Pharmacopeia (USP) Reference Standard; Lycopene, Pharmaceutical Secondary Standard; Certified Reference Material; Lycopene, Redivivo(TM), 10% FS, ~10% in corn oil, >=95.0% (sum of isomers); 2,6,10,14,19,23,27,31-Octamethyl-dotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-octamethyl-, (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-Octamethyl-, (all-E)-; LYC, LYCOPENE, Lycopene 7, Lycopene all-trans-, Lycopene, all-trans-, Lycopene, all-trans- (8CI), Lycopene (VAN), Natural yellow 27, NCGC00166291-01, NCGC00166291-02, NSC407322, NSC 407322
    Click to Show/Hide
Species Origin Daucus carota ...     Click to Show/Hide
Daucus carota
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Apiales
Family: Apiaceae
Genus: Daucus
Species: Daucus carota
Viola tricolor
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Malpighiales
Family: Violaceae
Genus: Viola
Species: Viola tricolor
Disease Prostate cancer [ICD-11: 2C82] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.863
 
MDCK Permeability
 -4.723
 
PAMPA
 - -
 
HIA
 - - -
 
Distribution
VDss
 0.084
 
PPB
 96.5%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 -
CYP1A2 substrate
 -
CYP2C19 inhibitor
 +++
CYP2C19 substrate
 - -
CYP2C9 inhibitor
 - -
CYP2C9 substrate
 ++
CYP2D6 inhibitor
 ++
CYP2D6 substrate
 +++
CYP3A4 inhibitor
 +
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 +++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 +++
HLM Stability
 +++
 
Excretion
CLplasma
 9.787
 
T1/2
 0.46
Toxicity
DILI
 - - -
 
Rat Oral Acute Toxicity
 +
 
FDAMDD
 -
 
Respiratory
 ++
 
Human Hepatotoxicity
 +
 
Ototoxicity
 +
 
Drug-induced Nephrotoxicity
 +
 
Drug-induced Neurotoxicity
 ++
 
Hematotoxicity
 -
 
Genotoxicity
 - - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C40H56
PubChem CID
446925
Canonical SMILES
CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C)C)C
InChI
1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+
InChIKey
OAIJSZIZWZSQBC-GYZMGTAESA-N
CAS Number
CAS 502-65-8
Herb ID
HBIN033972
ETMC ID
4317
SymMap ID
SMIT16376
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression p105  Molecule Info 
Pathway MAP
                    In-vitro Model HeLa CVCL_0030 Endocervical adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)		 Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-kappaB) pathway.
          Eicosapentaenoic acid      Inherited coagulation factor deficiency     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
Up-regulation Expression FAS  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation mTOR  Molecule Info 
Pathway MAP
                    In-vitro Model HT-29 CVCL_0320 Colon adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)		 Low concentration of lycopene and EPA could synergistically inhibit the proliferation of colon cancer cells. The inhibitory mechanism was associated with suppression of phosphatidylinositol 3-kinase/Akt signaling pathway.
          T0901317      Lung cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression ABCA1  Molecule Info 
Pathway MAP
Up-regulation Expression NR1H3  Molecule Info 
Pathway MAP
Up-regulation Expression PPAR-gamma  Molecule Info 
Pathway MAP
                    In-vitro Model DU145 CVCL_0105 Prostate carcinoma Homo sapiens
PC-3 CVCL_0035 Prostate carcinoma Homo sapiens
                    Experimental
                    Result(s)		 Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway.
          Anti-PD-1 antibody      Melanoma     Click to Show/Hide the Molecular Data of This Drug
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [5]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Up-regulation Expression IFNG  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation JAK-2  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation STAT3  Molecule Info 
Pathway MAP
                    In-vivo Model Lewis lung carcinoma (LLC) cells (1*106) were injected in the rear flak of C57BL/6 mice.
                    Experimental
                    Result(s)		 Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells.
Target and Pathway
Target(s) DNA-binding factor KBF1 (p105)  Molecule Info  [6]
Kelch-like ECH-associated protein 1 (KEAP1)  Molecule Info  [7]
Nuclear factor erythroid 2-related factor 2 (Nrf2)  Molecule Info  [7]
KEGG Pathway Protein processing in endoplasmic reticulum Click to Show/Hide
2 MAPK signaling pathway
3 Ras signaling pathway
4 cAMP signaling pathway
5 Chemokine signaling pathway
6 NF-kappa B signaling pathway
7 HIF-1 signaling pathway
8 Sphingolipid signaling pathway
9 PI3K-Akt signaling pathway
10 Apoptosis
11 Osteoclast differentiation
12 Toll-like receptor signaling pathway
13 NOD-like receptor signaling pathway
14 RIG-I-like receptor signaling pathway
15 Cytosolic DNA-sensing pathway
16 T cell receptor signaling pathway
17 B cell receptor signaling pathway
18 TNF signaling pathway
19 Neurotrophin signaling pathway
20 Prolactin signaling pathway
21 Adipocytokine signaling pathway
22 Non-alcoholic fatty liver disease (NAFLD)
23 Cocaine addiction
24 Epithelial cell signaling in Helicobacter pylori infection
25 Shigellosis
26 Salmonella infection
27 Pertussis
28 Legionellosis
29 Leishmaniasis
30 Chagas disease (American trypanosomiasis)
31 Toxoplasmosis
32 Amoebiasis
33 Tuberculosis
34 Hepatitis C
35 Hepatitis B
36 Measles
37 Influenza A
38 HTLV-I infection
39 Herpes simplex infection
40 Epstein-Barr virus infection
41 Pathways in cancer
42 Transcriptional misregulation in cancer
43 Viral carcinogenesis
44 MicroRNAs in cancer
45 Pancreatic cancer
46 Prostate cancer
47 Chronic myeloid leukemia
48 Acute myeloid leukemia
49 Small cell lung cancer
50 Inflammatory bowel disease (IBD)
NetPath Pathway IL5 Signaling Pathway Click to Show/Hide
2 IL1 Signaling Pathway
3 TCR Signaling Pathway
4 IL2 Signaling Pathway
5 TNFalpha Signaling Pathway
6 Leptin Signaling Pathway
Panther Pathway Apoptosis signaling pathway Click to Show/Hide
2 T cell activation
Pathwhiz Pathway Intracellular Signalling Through Adenosine Receptor A2a and Adenosine Click to Show/Hide
2 Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells Click to Show/Hide
2 BCR signaling pathway
3 LPA receptor mediated events
4 Atypical NF-kappaB pathway
5 Canonical NF-kappaB pathway
6 CD40/CD40L signaling
7 IL12-mediated signaling events
8 Alternative NF-kappaB pathway
9 Osteopontin-mediated events
10 Angiopoietin receptor Tie2-mediated signaling
11 Signaling events mediated by HDAC Class I
12 Regulation of Telomerase
13 IL1-mediated signaling events
14 Glucocorticoid receptor regulatory network
15 TNF receptor signaling pathway
16 IL2 signaling events mediated by PI3K
17 Ceramide signaling pathway
18 amb2 Integrin signaling
19 IL23-mediated signaling events
20 HIV-1 Nef: Negative effector of Fas and TNF-alpha
21 EPO signaling pathway
Reactome Activation of NF-kappaB in B cells Click to Show/Hide
2 RIP-mediated NFkB activation via ZBP1
3 Regulated proteolysis of p75NTR
4 NF-kB is activated and signals survival
5 Senescence-Associated Secretory Phenotype (SASP)
6 FCERI mediated NF-kB activation
7 DEx/H-box helicases activate type I IFN and inflammatory cytokines production
8 Transcriptional regulation of white adipocyte differentiation
9 TAK1 activates NFkB by phosphorylation and activation of IKKs complex
10 Interleukin-1 processing
11 IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
12 IkBA variant leads to EDA-ID
13 CLEC7A (Dectin-1) signaling
14 CD209 (DC-SIGN) signaling
15 CLEC7A/inflammasome pathway
16 MAP3K8 (TPL2)-dependent MAPK1/3 activation
17 TRAF6 mediated NF-kB activation
WikiPathways Oxidative Stress Click to Show/Hide
2 Transcriptional activation by NRF2
3 NRF2 pathway
4 Nuclear Receptors Meta-Pathway
5 Aryl Hydrocarbon Receptor Pathway
6 Mesodermal Commitment Pathway
7 Aryl Hydrocarbon Receptor
8 Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
9 Arylhydrocarbon receptor (AhR) signaling pathway
10 Toll-like receptor signaling pathway
11 DNA Damage Response (only ATM dependent)
12 SIDS Susceptibility Pathways
13 TCR Signaling Pathway
14 Notch Signaling Pathway
15 TGF Beta Signaling Pathway
16 IL-4 Signaling Pathway
17 Apoptosis Modulation by HSP70
18 MAPK Signaling Pathway
19 Myometrial Relaxation and Contraction Pathways
20 IL1 and megakaryotyces in obesity
21 Apoptosis-related network due to altered Notch3 in ovarian cancer
22 Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
23 Hair Follicle Development: Organogenesis (Part 2 of 3)
24 Hair Follicle Development: Induction (Part 1 of 3)
25 Selenium Metabolism and Selenoproteins
26 Cardiac Hypertrophic Response
27 Cytosolic sensors of pathogen-associated DNA
28 Fc epsilon receptor (FCERI) signaling
29 Transcriptional Regulation of White Adipocyte Differentiation
30 Signaling by the B Cell Receptor (BCR)
31 TAK1 activates NFkB by phosphorylation and activation of IKKs complex
32 Structural Pathway of Interleukin 1 (IL-1)
33 EBV LMP1 signaling
34 T-Cell Receptor and Co-stimulatory Signaling
35 Apoptosis
36 BDNF signaling pathway
37 Integrated Pancreatic Cancer Pathway
38 Oncostatin M Signaling Pathway
39 Corticotropin-releasing hormone
40 AGE/RAGE pathway
41 TNF alpha Signaling Pathway
42 B Cell Receptor Signaling Pathway
43 TSLP Signaling Pathway
44 IL17 signaling pathway
45 Neural Crest Differentiation
46 TWEAK Signaling Pathway
47 Leptin signaling pathway
48 RANKL/RANK Signaling Pathway
49 Integrated Breast Cancer Pathway
50 Signalling by NGF
51 IL-1 signaling pathway
52 TCR signaling
53 RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
54 Interleukin-1 signaling
55 Interleukin-1 processing
56 Apoptosis Modulation and Signaling
57 Folate Metabolism
58 TFs Regulate miRNAs related to cardiac hypertrophy
59 MicroRNAs in cardiomyocyte hypertrophy
60 Vitamin B12 Metabolism
61 Selenium Micronutrient Network
62 Regulation of toll-like receptor signaling pathway
63 Osteopontin Signaling
References
Reference 1 ClinicalTrials.gov (NCT01443026) The Effects of Lycopene on High Risk Prostatic Tissue
Reference 2 Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-kappaB) pathway. Turk J Med Sci. 2021 Feb 26;51(1):368-374.
Reference 3 Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells. J Nutr Biochem. 2009 Jun;20(6):426-34.
Reference 4 Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway. J Nutr Biochem. 2012 Sep;23(9):1155-62.
Reference 5 Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell Int. 2019 Mar 21;19:68.
Reference 6 The synergistic anti-inflammatory effects of lycopene, lutein, Beta-carotene, and carnosic acid combinations via redox-based inhibition of NF-KappaB signaling. Free Radic Biol Med. 2012 Oct 1;53(7):1381-91.
Reference 7 Natural ingredients-derived antioxidants attenuate H(2)O(2)-induced oxidative stress and have chondroprotective effects on human osteoarthritic chondrocytes via Keap1/Nrf2 pathway. Free Radic Biol Med. 2020 May 20;152:854-864.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link